Abstract:Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline. Animal studies and early clinical trials support its use in several neurological diseases. In animal spinal cord injury models, minocycline improved neurological and histological outcomes, reduced neuronal and oligodendroglial apoptosis, decreased microglial activation and reduced inflammation. A single-centre, human, double-blind, randomized, placebo-controlled study of minocycline administration after spinal cord injury was undertaken for the purposes of dose optimization, safety assessment and to estimate outcome changes and variance. Neurological, functional, pharmacological and adverse event outcomes were compared between subjects administered 7 days of intravenous minocycline (n = 27) or placebo (n = 25) after acute traumatic spinal cord injury. The secondary outcome used to assess neurological differences between groups that may warrant further investigation was motor recovery over 1 year using the American Spinal Cord Injury Association examination. Recruitment and analyses were stratified by injury severity and injury location a priori given the expected influence of these on the sensitivity of the motor exam. Minocycline administered at higher than previously reported human doses produced steady-state concentrations of 12.7 µg/ml (95% confidence interval 11.6-13.8) in serum and 2.3 µg/ml (95% confidence interval 2.1-2.5) in cerebrospinal fluid, mimicking efficacious serum levels measured in animal studies. Transient elevation of serum liver enzymes in one patient was the only adverse event likely related to the study drug. Overall, patients treated with minocycline experienced six points greater motor recovery than those receiving placebo (95% confidence interval -3 to 14; P = 0.20, n = 44). No difference in recovery was observed for thoracic spinal cord injury (n = 16). A difference of 14 motor points that approached significance was observed in patients with cervical injury (95% confidence interval 0-28; P = 0.05, n = 25). Patients with cervical motor-incomplete injury may have experienced a larger difference (results not statistically significant, n = 9). Functional outcomes exhibited differences that lacked statistical significance but that may be suggestive of improvement in patients receiving the study drug. The minocycline regimen established in this study proved feasible, safe and was associated with a tendency towards improvement across several outcome measures. Although this study does not establish the efficacy of minocycline in spinal cord injury the findings are encouraging and warrant further investigation in a multi-centre phase III trial. ClinicalTrials.gov number NCT00559494.

MINocyclinE to Reduce inflammation and blood‐brain barrier leakage in small Vessel diseAse (MINERVA): A phase II, randomized, double‐blind, placebo‐controlled experimental medicine trial

Minocycline Reduces Intracerebral Hemorrhage-Induced Brain Injury

Minocycline Attenuates Brain Edema, Brain Atrophy and Neurological Deficits after Intracerebral Hemorrhage.

Minocycline decreases blood-brain barrier permeability following aneurysmal subarachnoid hemorrhage: a randomized, double-blind, controlled trial

Minocycline in Severe Cerebral Amyloid Angiopathy: A Single-Center Cohort Study

Immune regulation and blood-brain barrier permeability in cerebral small vessel disease: study protocol of the INflammation and Small Vessel Disease (INSVD) study - a multicentre prospective cohort study

Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial

Early Treatment of Minocycline Alleviates White Matter and Cognitive Impairments after Chronic Cerebral Hypoperfusion

Hypoxia-Induced Neuroinflammatory White-Matter Injury Reduced by Minocycline in SHR/SP

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration

Chronic Treatment With Minocycline Preserves Adult New Neurons And Reduces Functional Impairment After Focal Cerebral Ischemia

The Minocycline Ameliorated the Synaptic Plasticity Impairment in Vascular Dementia

Abstract TMP110: Minocycline Reduces Hypoxia-mediated BBB Disruption by Protecting TJP Degradation and Promoting Angiogenesis in SHR/SP with Chronic White-matter Injury

Attenuation of Acute Stroke Injury in Rat Brain by Minocycline Promotes Blood–brain Barrier Remodeling and Alternative Microglia/macrophage Activation During Recovery

Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury

Abstract W MP42: Early Treatment with Minocycline Promotes Neurovascular Remodeling of Tight Junctions Facilitating Recovery after Stroke in Rat Brain

Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia.

Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1α through SIRT-3/PHD-2 degradation pathway

Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study

Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration

Minocycline is Effective in Intracerebral Hemorrhage by Inhibition of Apoptosis and Autophagy.